"I would say the fact that we performed 754 HoLEP procedures in 2024 is a reflection of the efficiency and the high quality of care that you receive at Northwestern," says Amy E. Krambeck, MD. In this ...

In this video, Bradley Roth, MS4, and Scott D. Lundy, MD, PhD, HCLD, outline the background and rationale for the study, “Routine Sperm Cryopreservation before Vasectomy Is Not Cost-Effective and Does ...

MPS2 test detects 94% of GG2 or higher prostate cancers using non-DRE urine samples, outperforming PSA and PCPTrc in accuracy. MPS2 models could reduce unnecessary biopsies by 36% to 42%, compared to ...

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options ...

Urologists emphasized the importance of AUA guidelines, patient context, and clinical judgment in managing low-grade UTUC. Challenges in diagnosis and treatment include obtaining adequate biopsies and ...

Panelists discuss how low-risk non–muscle-invasive bladder cancer (NMIBC) requires transurethral resection of bladder tumor (TURBT) with surveillance. Intermediate-risk disease needs adjuvant ...

WNT9B gene mutations significantly increase prostate cancer risk, with a 2- to 12-fold elevation observed across multiple studies. Specific variants, WNT9B E152K and Q47R, show significant ...

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC ...

MiR-371a-3p demonstrates high sensitivity and specificity, outperforming traditional tumor markers in testicular cancer diagnosis and monitoring. MiR-371a-3p shows potential in early relapse detection ...

Signati's Separo system achieved FDA de novo market clearance application after demonstrating safety and effectiveness in GLP data and an IDE study. The Separo system enables a transdermal vasectomy, ...

Experts discuss the variability of non-muscle invasive bladder cancer (NMIBC) in terms of staging and risk stratification and how they navigate these diagnoses with their patients.

This video segment discusses patient selection criteria for choosing between the original brand, generic, and micronized versions of abiraterone.